Aurobindo gets FDA approval for generic Revatio

DAYTON, N.J. — Aurobindo Pharma announced Wednesday that it had received Food and Drug Administration approval for its sildenafil tablets, a generic version of Pfizer’s Revatio. The drug is indicated to treat pulmonary arterial hypertension in adults. 

 

The drug, which will be available in 20-mg tablets, had an approximate market size of $80 million in the United States, according to IMS Health data for the 12 months ended September 2015.